World's First Entirely AI-Designed Vaccine Successfully Completes Phase I Human Trial

World's First Entirely AI-Designed Vaccine Successfully Completes Phase I Human Trial

In a landmark shift for vaccinology, researchers at the University of Cambridge and the biotechnology company DIOSynVax have developed and successfully tested the world's first vaccine designed entirely by artificial intelligence and machine-learning systems. Rather than targeting a single circulating pathogen strain, the experimental vaccine uses an AI-designed "super-antigen" to protect against entire virus families, including current and future coronavirus variants, bird flu, and Ebola-related threats.¹

The results of the Phase I clinical trial, sponsored by the University Hospital Southampton NHS Foundation Trust and published in the June 2026 edition of the Journal of Infection, demonstrated that the universal Sarbecovirus vaccine is safe and triggers a broad immune response.

The AI-Driven "Super-Antigen" Design

Traditional vaccines target specific circulating strains, which frequently mutate and require constant updates (such as annual flu shots or updated COVID-19 boosters). The Cambridge team used AI to analyze thousands of genomic sequences from previous outbreaks, currently circulating pathogens, and animal-borne viruses to locate essential biological features that remain unchanged across an entire virus family.

By targeting parts of the virus that are essential to its survival and cannot easily mutate without weakening the pathogen, the AI constructed a synthetic "super-antigen." Professor Jonathan Heeney, head of the Lab of Viral Zoonotics at the University of Cambridge, explained the paradigm shift:

"You hoover up all the genomic sequences; what’s known from around the world, from past outbreaks and current outbreaks, and you do some basic structural science... We take all these different sequences…and we think, ‘OK, what’s consistent amongst them, what’s not changing, what is essential for their life’ and that’s what we target. It not only predicts, but it targets what is essential for that virus family. We’re targeting something in a virus family, which the virus can’t change easily."

Clinical Trial Success and Delivery Technology

The Phase I trial evaluated the universal Sarbeco vaccine in healthy volunteers aged 18 to 50. The vaccine was delivered as a DNA-based formulation using a needle-free microfluid jet system that uses high pressure to deliver the vaccine material directly through the skin into cells.

The trial successfully established safety and demonstrated modest immune responses against multiple coronavirus targets, including SARS-CoV-2, the original SARS virus, and related bat coronaviruses that have not yet jumped to humans. A larger Phase II study involving over 200 participants is planned to further evaluate efficacy.

Broad Applications: H5N1 Bird Flu and Ebola

The underlying AI platform is currently being deployed to design universal vaccines for other high-consequence pathogens:

• H5N1 Bird Flu: The widespread transmission of H5N1 among wild birds, mammals, and U.S. dairy cattle has heightened pandemic fears. The AI vaccine aims to target conserved regions across multiple clades, including highly lethal Southeast Asian strains.
• Ebola: Current outbreaks in the Democratic Republic of Congo involve the rare Bundibugyo strain, which is not covered by existing vaccines. The AI-designed Ebola vaccine aims to provide cross-protection against all species in the filovirus family.

As Professor Heeney noted:

"This is about making vaccines that not just protect us from today's viruses, but the ones that haven’t yet happened."